EU Malaria Fund

The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address EU Malaria Fund: Transforming Global Health Through Strategic Investment The EU Malaria Fund is a public-private partnership with the European Union, international organizations, corporations, and civic society to tackle critical market failures in infectious disease innovation. Investment Phase Complete - Portfolio Deployed Our strategic investment phase has successfully concluded, deploying capital across high-impact malaria product development projects. We've invested in next-generation vaccine development platforms and breakthrough therapeutic compounds specifically engineered to overcome drug resistance—addressing one of malaria's most pressing challenges. Three-Market Strategy Driving Impact Our portfolio targets premium markets (travel/military sectors), volume opportunities through GAVI partnerships, and platform technologies with cross-indication potential extending to neurodegenerative diseases. This diversified approach maximizes social impact and enables commercial viability. Portfolio Highlights: Next-generation vaccine platforms with proven milestone achievements Resistance-breaking therapeutic compounds with promising efficacy profiles Secondary applications in neurodegeneration and severe asthma Market Impact at Scale With 240 million annual malaria cases and climate change expanding endemic zones, our investments address a $9.6 trillion travel industry increasingly exposed to malaria risk. Every dollar invested generates $36 in economic growth within endemic regions through reduced healthcare costs and increased productivity. Proven Investment Success All our malaria projects have successfully passed key milestones with positive outcomes. Portfolio companies have secured follow-on grant funding and continue advancing their developments. These projects